Recurrent Cytokine Storm in SARS-CoV-2 Infected Patients with Hematolymphoid Malignancy: A New Perspective

Sujeet Kamtalwar

Cancer patients, especially with hematological malignancies are at higher risk of contracting coronavirus disease 2019 (COVID-19) because of the immunosuppressed state both due to the malignancy and medications administered as a part of cancer management. Cytokine storm or acute respiratory distress syndrome (ARDS) is the major cause of deaths due to COVID-19. However, delayed cytokine storm can be seen until 21 days of illness. Herein, we report two patients of hematolymphoid malignancy with COVID-19 who had recurrent cytokine storm which is uncommon.

India alone has witnessed over 41 million cases of COVID-19 with approximately 1.19% mortality.[1] Though severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be asymptomatic or present with mild symptoms in majority, patients can progress to ARDS. Seventeen studies from 2,486 hospitals over 5 countries performed from the beginning of the pandemic to July 2020 reported a variable incidence of ARDS in SARS-CoV-2 infection ranging from 2 to 68%.[2] Most cases with COVID-19 and ARDS were either elderly or having comorbidities.[3] According to a meta-analysis[4] performed in 2020, cancer patients with COVID-19 infection were associated with a 28% day-28 mortality, much higher as compared with noncancer patients. We reported from our institute that cancer patients have 10 times higher mortality as compared with noncancer patients (10% vs. 1.1%).[5] However, repeated episodes of ARDS in the same patient have not been described in literature. We present here two case scenarios of patients with B cell non-Hodgkin lymphoma (B-NHL) who presented with two discrete episodes of severe COVID-19 with cytokine storm with an interim asymptomatic period.

Declaration of Patient Consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient has given his consent for his images and other clinical information to be reported in the journal. The patient understands that his name and initials will not be published and due efforts will be made to conceal his identity, but anonymity cannot be guaranteed.

The manuscript has been read and approved by all the authors, that the requirements for authorship have been met, and that each author believes that the manuscript represents honest work.

Publikationsverlauf

Artikel online veröffentlicht:
11. August 2023

• References

• 1 Accessed January 31, 2022, at: https://www.mohfw.gov.in/
• 2 Tzotzos SJ, Fischer B, Fischer H, Zeitlinger M. Incidence of ARDS and outcomes in hospitalized patients with COVID-19: a global literature survey. Crit Care 2020; 24 (01) 516
• 3 Sanyaolu A, Okorie C, Marinkovic A. et al. Comorbidity and its impact on patients with COVID-19. SN Compr Clin Med 2020; 2 (08) 1069-1076
• 4 Assaad S, Zrounba P, Cropet C, Blay JY. ONCOVID-19 study Consortium. Mortality of patients with solid and haematological cancers presenting with symptoms of COVID-19 with vs without detectable SARS-COV-2: a French nationwide prospective cohort study. Br J Cancer 2021; 125 (05) 658-671
• 5 Mirgh SP, Gokarn A, Rajendra A. et al. Clinical characteristics, laboratory parameters and outcomes of COVID-19 in cancer and non-cancer patients from a tertiary cancer centre in India. Cancer Med 2021; 10 (24) 8777-8788
• 6 Goldman JD, Lye DCB, Hui DS. et al; GS-US-540-5773 Investigators. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med 2020; 383 (19) 1827-1837
• 7 Horby P, Lim WS, Emberson JR. et al; RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 2021; 384 (08) 693-704
• 8 Ranjbar K, Moghadami M, Mirahmadizadeh A. et al. Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial. BMC Infect Dis 2021; 21 (01) 337
• 9 Pang J, Xu F, Aondio G. et al. Efficacy and tolerability of bevacizumab in patients with severe Covid-19. Nat Commun 2021; 12 (01) 814
• 10 Mukherjee A, Anand T, Agarwal A. et al. SARS-CoV-2 re-infection: development of an epidemiological definition from India. Epidemiol Infect 2021; 149: e82
• 11 Liang W, Guan W, Chen R. et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020; 21 (03) 335-337
• 12 Zhang H, Han H, He T. et al. Clinical characteristics and outcomes of COVID-19-infected cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst 2021; 113 (04) 371-380
• 13 Borah P, Mirgh S, Sharma SK. et al; AIIMS Hematology Alumni Group. Effect of age, comorbidity and remission status on outcome of COVID-19 in patients with hematological malignancies. Blood Cells Mol Dis 2021; 87: 102525
• 14 Shah V, Ko Ko T, Zuckerman M. et al. Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King's College Hospital experience. Br J Haematol 2020; 190 (05) e279-e282
• 15 Avanzato VA, Matson MJ, Seifert SN. et al. Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer. Cell 2020; 183 (07) 1901-1912.e9
• 16 Kos I, Balensiefer B, Roth S. et al. Prolonged course of COVID-19-associated pneumonia in a B-cell depleted patient after rituximab. Front Oncol 2020; 10: 1578
• 17 Yasuda H, Tsukune Y, Watanabe N. et al. Persistent COVID-19 pneumonia and failure to develop anti-SARS-CoV-2 antibodies during rituximab maintenance therapy for follicular lymphoma. Clin Lymphoma Myeloma Leuk 2020; 20 (11) 774-776
• 18 Baang JH, Smith C, Mirabelli C. et al. Prolonged severe acute respiratory syndrome coronavirus 2 replication in an immunocompromised patient. J Infect Dis 2021; 223 (01) 23-27
• 19 Helleberg M, Niemann CU, Moestrup KS. et al. Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of remdesivir therapy. J Infect Dis 2020; 222 (07) 1103-1107